What Life Sciences CEOs Are Losing Sleep Over in 2026

There is a version of the life sciences CEO that the industry tends to celebrate: visionary, decisive, comfortable with risk. And then there is the version that shows up in confidential surveys — navigating a funding crisis with a 60-day clock, managing a board that isn’t fully aligned, wondering if anyone else in the room understands what the job actually feels like.

In early 2026, The Vanguard Network surveyed 33 CEOs and senior leaders across biotech, medtech, diagnostics and adjacent fields to understand where the real pressure is coming from — not the headline priorities, but the texture and urgency of them. The results are striking in their consistency, and in a few places, quietly sobering.

Capital is not a priority — it is the condition

The survey’s most arresting finding is also its simplest: Three-quarters of respondents named attracting investors or partners as their single most urgent challenge (see Figure 1 below). Not one issue among several, but the one that eclipses everything else. In a multiselect survey where respondents could flag as many priorities as applied, 76% still checked this box — a degree of concentration that is unusual and telling.

What makes this notable is not just the number but what it signals about the operating environment. The life sciences funding market has tightened materially since 2022, and the leaders in this survey are feeling it acutely. For a significant cohort — particularly those at Series A or pre-revenue stage — the timeline is not strategic. Nearly a third described their situation as immediate, requiring resolution within 30 to 60 days. This is not capital planning. It is survival management.

Capital pressure also cascades. Many of the leaders who flagged capital as their primary concern also selected regulatory uncertainty and clinical development strategy as concurrent pressures — suggesting that the CEO’s job in 2026 is less about solving one hard problem than about managing several interlocking ones simultaneously, each of which affects the others.

Regulatory disruption as ambient condition

Regulatory and policy uncertainty ranked third among all priorities, selected by 36% of respondents. Two participants named it as their most pressing single issue. But the more revealing signal is how it appears in the data: not as a standalone crisis, but as a persistent co-occurrence alongside capital and R&D concerns.

Leaders are not managing FDA instability in isolation. They are managing it while also deciding which programs to advance and which investors to pursue.

The disruptions are specific and operational. FDA staffing changes and shifting guidance timelines have direct program implications for companies in clinical-stage development. Trade policy and tariff exposure have introduced new vulnerability into manufacturing and supply chain planning — not an abstract policy discussion, but a concrete variable in decisions being made this quarter. For companies with China-adjacent manufacturing partnerships or intellectual property positions, geopolitical risk has entered the strategic conversation in a way it had not in prior cycles.

What this cohort of leaders is asking for, notably, is not compliance support. It is sense-making: help translating a rapidly shifting regulatory and policy landscape into strategic options. The ask is for a thinking partner who can help them reason under uncertainty, not a consultant who can file the right paperwork.

The sequencing problem: R&D and commercial strategy under pressure

R&D and clinical development strategy was the second most frequently selected priority, cited by 42% of respondents. Commercialization, market access and pricing was named by 30%. Together, they represent what might be called the execution layer of life sciences leadership — the decisions that determine whether science translates into value.

What the data reveal, however, is that neither set of decisions is being made in a normal strategic environment. Clinical sequencing choices — which programs to advance first, which to defer, how to stage development to extend runway — are being made under capital pressure, with compressed time horizons and high stakes for each call. For companies pursuing orphan designations or novel indication strategies, regulatory and clinical strategy have effectively merged into a single conversation.

On the commercial side, the market access environment has genuinely become more difficult. Inflation Reduction Act pricing provisions, evolving coverage policies and increasing scrutiny of specialty and rare disease pricing have narrowed the window between regulatory approval and commercial viability. Respondents who flagged commercialization as a priority overwhelmingly described their timeline as immediate or near-term — these are not horizon-scanning conversations. They are active decisions on timing, channel, pricing and partnership structure, being made right now.

Urgency is the defining variable

Perhaps the most significant structural finding in the survey is not about any specific priority — it is about time. Seventy-five percent of respondents described their most pressing issue as immediate (needing attention within 30 to 60 days) or near-term (this quarter). Only 24% named a six-to-12-month horizon (see Figure 2).

This distribution matters because it changes what kind of leadership support is actually useful. Long-horizon strategic planning is a luxury most of these leaders cannot afford right now. Advisory models, peer networks and management frameworks designed for a slower, more deliberate operating tempo are not built for the environment these CEOs are actually in. What the data call for is support that can meet leaders in their actual timeframe — fast, contextual and calibrated to the specific pressure they are navigating today.

The advisory gap — and the loneliness beneath it

The survey’s findings on advisory needs complicate the picture in an important way. Despite high urgency across virtually all priorities, 45% of respondents said they are not currently looking for outside advisory support. This is not complacency — it more likely reflects a combination of factors: a belief that the current challenge is manageable internally, skepticism about whether formal advisory structures can keep pace with the operating tempo and, for founder-led companies especially, a cultural disposition toward self-reliance.

Among those who do want support, the preference is unambiguous (see Figure 3 below). Thirty-six percent named a CEO sounding board or trusted advisor as their preferred format — far ahead of formal consulting engagements, ongoing advisory relationships or structured programs. The desire is for a senior peer who understands the full context of the CEO’s situation and can help them think things through. Not a project. Not a deliverable. A relationship.

One open comment in the survey stands apart from the rest in its directness. A respondent requested “techniques and resources to deal with the inherent loneliness of the CEO role.” It would be easy to read this as an outlier. It is not. It is a structural feature of early-stage leadership that almost never surfaces in formal surveys, which is precisely why it is worth dwelling on.

The life sciences CEO carries the full weight of their company’s challenges — scientific, commercial, financial, organizational — while managing a board that expects confidence, a team that needs direction and investors who want returns. There is rarely someone in that equation whose job is to be on the CEO’s side. The survey suggests that this absence is felt, even if it is rarely named.

What the industry should take seriously

The picture that emerges from this data is not of an industry in decline. It is of an industry under genuine pressure, populated by capable leaders who are doing more than most people outside their companies understand. The funding environment is difficult. The regulatory environment is volatile. The execution demands are high. And the support infrastructure — in the form of peer networks, advisory models and honest dialogue about the experience of leadership — has not kept pace.

Three things follow from this. First, capital strategy is not a standalone function. For the majority of life sciences CEOs, it is the context within which every other decision is made. Any framework for life sciences leadership that treats fundraising as one priority among many misunderstands the current environment.

Second, the short time horizons these leaders are operating on demand advisory models that match their tempo. Structured engagements with long onboarding periods, generic best-practice frameworks and deliverables measured in quarters are not what these CEOs are asking for. They are asking for a trusted peer who can help them think through a hard decision by Friday.

Third, and perhaps most importantly: The loneliness of the CEO role is not a soft topic. It is a leadership infrastructure problem. The most effective intervention may not be a new advisory product or a better peer network — though both matter. It may simply be creating more honest space for life sciences leaders to name what the job actually feels like, and to find others who recognize it.

Ken Banta is founder and CEO of The Vanguard Network, and a member of Pharmaceutical Executive’s Editorial Advisory Board

Note: The Vanguard Network’s Life Sciences CEO programming convenes senior executives in peer exchange forums across New York, Boston, Chicago and Washington, D.C. Survey data cited in this article are drawn from the Vanguard Network Life Sciences CEO Advisory Resource Survey (N=33, February–May 2026).